New epilepsy drug shows promise for long-term seizure control

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to understand and voluntarily sign the written informed consent form for this extension trial. * Considered reliable by the investigator and capable of complying with the study protocol, including completing seizure diaries, attending study visits, and adhering to treatment. * Completed the 12-week double-blind maintenance treatment period of the preceding QF-Brivaracetam-POS-301 trial. * Judged by the investigator to be likely to benefit from long-term treatment with brivaracetam. * Female subjects of childbearing potential must have a negative pregnancy test within 7 days prior to the first study drug administration and agree to use a medically acceptable method of contraception during the trial and for 3 months after the last dose of study drug. Male subjects with partners of childbearing potential must agree to use effective contraception during the trial and for 3 months after the last dose of study drug. Exclusion Criteria: * Known hypersensitivity to brivaracetam, levetiracetam, or other pyrrolidine derivatives; or history of multiple severe allergies. * Any medical or psychiatric condition that, in the investigator's opinion, may jeopardize or impair the subject's ability to participate in the trial; or clinically significant abnormal laboratory values including: calculated CrCL \< 30 mL/min (Cockcroft-Gault formula), platelets \< 80×10\^9/L, neutrophils \< 1.8×10\^9/L, ALT/AST/ALP \> 2×ULN, or GGT \> 3×ULN. * QTc interval \> 450 ms on 12-lead ECG, confirmed by repeat testing (average of 3 measurements remains \> 450 ms). * Female subjects who are pregnant or breastfeeding. * History of suicide attempts (including actual attempts, interrupted attempts, aborted attempts, or preparatory acts/behavior) or current suicidal ideation, as assessed by the C-SSRS scale. * Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this trial.